Identification of Apo B48 and other novel biomarkers in amyotrophic lateral sclerosis patient fibroblasts

Written by Narayan M, Seeley KW, Jinwal UK

Amyotrophic lateral sclerosis (ALS) is one of the most prevalent neurodegenerative disorders. It is a rapidly progressive and fatal disease that affects motor neurons in the motor cortex, brain stem and spinal cord leading to atrophy of neurons responsible for voluntary muscle action including speech, movement and breathing [1]. Most patients with ALS die due to respiratory failure within 3–5 years of onset of symptoms [2]. While a majority of ALS cases (90–95%) are sporadic with patients demonstrating no clear risk factors for the disease, 5–10% of cases are familial where the disease-causing mutation is inherited dominantly. Genes implicated in development of...

To view the full article, please register now for access

It's completely free